

WEDNESDAY 20th MAY 2015 COMMENCING 10.30 AM

AT [THE ANGEL HOTEL](#), ABERGAVENNY, NP7 5EN

AGENDA

Enclosure

1. **Welcome and introduction**
2. **Apologies**
3. **Declarations of interest**
4. **Minutes of previous meeting** 1/AWMSG/0515
5. **Chairman's report (verbal update)**
6. **All Wales Choose Pharmacy Formulary** 2/AWMSG/0515
7. **Appraisal 1: Full Submission** 3/AWMSG/0515
Beclometasone dipropionate/formoterol fumarate (Fostair[®]) for the symptomatic treatment of patients with COPD, with a FEV1 < 50% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators Appendices
8. **Appraisal 2: Full Submission** 4/AWMSG/0515
Brentuximab vedotin (Adcetris[®]) for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option; as well as for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) Appendices
9. **National Prescribing Indicators 2015–2016: Slide Set** 5/AWMSG/0515
For information
10. **National Prescribing Indicators 2014–2015: Analysis of Prescribing Data to December 2014** 6/AWMSG/0515
For information
11. **All Wales Homecare Committee** 7/AWMSG/0515

To protect commercial confidentiality the following 2 appraisals will be conducted in private as they include an associated patient access scheme

- | | |
|---|----------------------------|
| 12. Appraisal 3: Full Submission (WPAS)
Pomalidomide (Imnovid®) in combination with dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy | 8/AWMSG/0515
Appendices |
| 13. Appraisal 4: Full Submission (PAS)
Enzalutamide (Xtandi®) for the treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated | 9/AWMSG/0515
Appendices |

The meeting will open to the public for the announcement of AWMSG's recommendations in relation to Appraisal 3 and 4

Date of next meeting: 17th June 2015 in Abergavenny